Scleroderma (also known as systemic sclerosis/SSc) is a rheumatologic disease that results in chronic hardening and tightening of connective tissues. It is one of a few rheumatic diseases that alters the appearance of the patient on the outside while it harms the internal organs. The program comprises doctors from rheumatology, pulmonary critical care, cardiology, gastroenterology, nephrology, dermatology, and anesthesiology, among others, with special expertise in SSc.

The team provides coordinated, multidisciplinary, and compassionate care for patients and all the parts of the body SSc affects, including the skin, lung, heart, kidneys, and gastrointestinal system. We also address functional, nutritional, psychological, gynecological, urological, and/or sexual health challenges, with the goals of improving quality of life, enhancing patient satisfaction, and achieving better outcomes.

The scleroderma research program aims to understand the causes of this complex disease and identify and develop new treatments. With expert doctors in clinic partnering with world class scientists in the laboratory, we work to bring research discoveries into our practice.

Yale has been designated as a Scleroderma Center by the Scleroderma Foundation.